NCT05349669 (JAFRONCPB) is a Phase 2 clinical trial of Jafron use during CPB in Cytokine Release Syndrome, sponsored by Anthea Hospital Bari.

Who is sponsoring NCT05349669?

NCT05349669 is sponsored by Anthea Hospital Bari.

What drugs are being tested in NCT05349669?

Interventions in NCT05349669: Jafron use during CPB.

What condition does NCT05349669 study?

NCT05349669 studies Cytokine Release Syndrome.

Is NCT05349669 still recruiting?

NCT05349669 is currently completed. Last updated 24 February 2023.

Last reviewed 2023-02-24 · How we verify

NCT05349669: JAFRONCPB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Jafron Haemoadsorption During Cardiopulmonary Bypass

Completed Phase 2 Last updated 24 February 2023

What this trial tests

Phase 2 trial testing Jafron use during CPB in Cytokine Release Syndrome in 40 participants. Completed in 15 September 2022.

Timeline

30 May 2022

Primary endpoint
15 September 2022

15 September 2022

Quick facts

Lead sponsor	Anthea Hospital Bari
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	40
Start date	30 May 2022
Primary completion	15 September 2022
Estimated completion	15 September 2022
Sites	1 location across Italy

Drugs / interventions tested

Jafron use during CPB — full drug profile →

Conditions studied

Cytokine Release Syndrome — all drugs for Cytokine Release Syndrome →

Sponsor

Anthea Hospital Bari

Who can join

Adults 10 to 100, any sex, with Cytokine Release Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cardiopulmonary bypass (CPB) is often associated with degrees of complex inflammatory response mediated by various cytokines. This response can, in severe cases, lead to systemic hypotension and organ dysfunction. Cytokine removal might therefore improve outcomes of patients undergoing cardiac surgery. Jafron is a device designed to remove cytokine from the blood using haemoadsorption (HA). This preliminary report aims to evaluate the potential of Jafron to decrease peri-operative cytokine levels in cardiac surgery.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Hemadsorption to Contain Postoperative Cell-Free Hemoglobin and Haptoglobin Preservation for Extended Cardiopulmonary Bypass Time in Cardiac Surgery for Acute Kidney Injuries Prevention.
Condello I, Morvillo JB, Fiore F, Teora V, et al · · 2024 · cited 4× · PMID 38748856 · DOI 10.21470/1678-9741-2023-0272

Verify or expand the search:

Other recruiting trials for Cytokine Release Syndrome

Currently open trials in the same condition.

NCT07169487 — Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study · Phase 1 · recruiting
NCT06447376 — Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab · Phase 1 · recruiting
NCT04975555 — Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associ · Phase 2 · active not recruiting

Other Anthea Hospital Bari trials

Trials by the same sponsor.

NCT05754294 — Electric Polarization of Red Blood Cells : A Cohort Study to Assess the Erythrocytes Membrane Integrity Through Charge C · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05349669 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anthea Hospital Bari
Last refreshed: 24 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05349669.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing